ARS Pharmaceuticals Inc <SPRY.OQ> expected to post a loss of 47 cents a share - Earnings Preview
ARS Pharmaceuticals Inc SPRY.OQ SPRY.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2025
The San Diego California-based company is expected to report a 2,655.3% increase in revenue to $13.776 million from $500 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for ARS Pharmaceuticals Inc is for a loss of 47 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $30.00, about 41.7% above its last closing price of $17.50
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.35 | -0.35 | -0.35 | Met | -1 |
Dec. 31 2025 | -0.10 | -0.14 | 0.49 | Beat | 450 |
Sep. 30 2024 | -0.15 | -0.15 | -0.20 | Missed | -35.6 |
Jun. 30 2024 | -0.13 | -0.12 | -0.13 | Missed | -11.4 |
Mar. 31 2024 | -0.12 | -0.11 | -0.11 | Met | 0 |
Dec. 31 2023 | -0.11 | -0.14 | -0.07 | Beat | 50 |
Sep. 30 2023 | -0.19 | -0.18 | -0.16 | Beat | 12.4 |
Jun. 30 2023 | -0.19 | -0.17 | -0.18 | Missed | -3.6 |
This summary was machine generated August 11 at 13:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
